306 related articles for article (PubMed ID: 33759081)
1. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
[No Abstract] [Full Text] [Related]
3. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
Front Immunol; 2024; 15():1395968. PubMed ID: 38846940
[TBL] [Abstract][Full Text] [Related]
4. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS).
Pina Vegas L; Hoisnard L; Bastard L; Sbidian E; Claudepierre P
RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597983
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi.
Asante K; Racsa P; Bloomfield A; Cornett D; Schwab P
J Manag Care Spec Pharm; 2023 Oct; 29(10):1109-1118. PubMed ID: 37776118
[No Abstract] [Full Text] [Related]
7. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
Mease PJ; Young P; Gruben D; Fallon L; Germino R; Kavanaugh A
Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
[TBL] [Abstract][Full Text] [Related]
9. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
10. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
Leung YY; Korotaeva TV; Candia L; Pedersen SJ; Bautista Molano W; Ruderman EM; Bisoendial R; Perez-Alamino R; Olsder W; Möller B; Grazio S; Gudu T; Mody GM; Pineda C; Raffayova H; Rohekar S; Goldenstein-Schainberg C; Gutierrez Urena SR; Casasola Vargas JC; Meghnathi B; Prasad R; Richette P; Miranda JRS; Malliotis N; Lindqvist U; Simon D; Ezeonyeji A; Soriano ER; FitzGerald O
J Rheumatol; 2023 Jan; 50(1):119-130. PubMed ID: 36243409
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
[TBL] [Abstract][Full Text] [Related]
14. Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis.
Jin Y; Chen SK; Lee H; Landon JE; Merola JF; Kim SC
J Manag Care Spec Pharm; 2021 Aug; 27(8):1106-1117. PubMed ID: 34337987
[No Abstract] [Full Text] [Related]
15. Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.
Littlejohn G; Leadbetter J; Butcher BE; Feletar M; O'Sullivan C; Smith T; Witcombe D; Ng HY; Youssef P
Clin Rheumatol; 2024 May; 43(5):1579-1589. PubMed ID: 38459357
[TBL] [Abstract][Full Text] [Related]
16. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS).
Pina Vegas L; Penso L; Sbidian E; Claudepierre P
RMD Open; 2023 Dec; 9(4):. PubMed ID: 38114199
[TBL] [Abstract][Full Text] [Related]
17. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
18. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
[TBL] [Abstract][Full Text] [Related]
19. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.
Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R
Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475
[TBL] [Abstract][Full Text] [Related]
20. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
